Method of prevention of parturient paresis in cows
FIELD: veterinary medicine.
SUBSTANCE: method comprises administering a homeopathic agent. The agent "Liarsin" is used, which is administered subcutaneously before calving into the biologically active points in the centre of the front and rear udder parts.
EFFECT: invention is highly effective for prevention of parturient paresis in cows.
4 cl, 2 tbl, 1 ex
The invention relates to veterinary medicine, in particular to methods of prevention of puerperal paresis in cows.
The known method of prevention of puerperal paresis in cows, including the use of drinking water immediately after calving in the amount of 1 liter for 5-7 days. The composition of the water: lysine - 15-20 g; methionine - 10-15 g; succinic acid, 2.5 g; propylene glycol - 100 g; glycerol - 60 g; vitamin B25 mg; Niacin 4 g; vitamin B125 mg; calcium lactate - 50 g; extract of grape skins - 500 mg (Patent RF №2370163 "Drinking water for cows" / Malkov M. A., Dankova T. V.; applicant and patentee Malkov M. A., T. V. Dankova - No. 2007117407/13; Appl. 10.05.2007. - publ. 20.11.2008).
However, the drug used in the method, multi-component and its fabrication requires the presence of an extract of grape skin, for the growth of which is not suitable for all climatic conditions, the preventive effect is quite significant doses of the drug.
The known method of therapy of puerperal paresis by the impact of acupuncture on acupuncture points (THE): 1, 8, 9, 12, 18, 21, 57, 59, 29, 68, 105, 106, 115, 118 and 119 described by G. V. Kaneevym (G. V. Kazeev Veterinary acupuncture (practical manual) - M.: RIO RGAZU, 2000. - S. 267).
However, in this method uses the 15 acupuncture points, to search which requires special knowledge, and b�long time, the loss of which can lead to death of the animal. Method is not applicable for the prevention of puerperal paresis, but only for its treatment.
The known method of prevention of puerperal paresis by intramuscular administration of a homeopathic drug "Katoren" in a dose of 5.0 ml per animal, starting with the 6th month of pregnancy 1 week, with the 7th of the month - 1 time per two weeks (the Use of drugs "HELMET" in animal husbandry (for the Description of drugs, schemes and methods of application) / the Group of companies "HELMET". - [B. M. I.]: [B. I.], 2010. - P. 12).
However, the preventive effect is quite significant doses of the drug.
The objective of the claimed invention is: reduce the cost of carrying out activities aimed at the treatment of puerperal paresis and decreased risk of postpartum paresis.
The technical result of the invention is the amount of homeopathic drug is about 2.5 times less than recommended doses of a prototype that lower the cost of ongoing veterinary measures and increasing the safety of livestock animals.
Said technical result is achieved in that used subcutaneous injections of homeopathic drug "Larsen" in biologically active points located bilaterally in the center of the front and rear Dol�th udder, which correspond to acupuncture points 118 and 119 described by G. V. Kaneevym, 7-10 and 14 to 20 days before calving at a dose of 0.5 ml.
The inventive method of treatment is illustrated by an example.
Cow Holstein-Frisian breed black-and-white suit in the amount of 22 goals. Pregnancy 250-260 days.
Prevention: subcutaneously into biologically active points located bilaterally in the center of the front and rear udder lobes, which correspond to acupuncture points 118 and 119 described by G. V. Kaneevym, was administered homeopathic drug "Larsen" in a dose of 0.5 ml for 7-10 and 14-20 days prior to calving.
Blood biochemistry (total protein, albumin, urea, glucose) in cows of the experimental group before the studies were below the physiological norm, with a high level of bilirubin (table 1).
After research in the experimental group there was a significant increase of total protein, 13.4% and albumin 16.3%.
In the control group showed a significant decrease in the level of potassium 34.8%.
Changes in other biochemical parameters in experimental and control groups were not statistically significant differences.
The results of the course of postnatal period is shown in table 2.
After calving in cows of the control group were recorded puerperal paresis in 1.7%, and 100% of the cows of the experimental group were no clinical signs of puerperal paresis. Biochemical indicators of blood of experimental animals was consistent with physiological norm.
The proposed method normalizes the metabolism of down-calving cows and contributes to the prevention of puerperal paresis. The amount of homeopathic drug is about 2.5 times less than recommended doses of a prototype that lower the cost of ongoing veterinary measures and increasing the safety of livestock animals.
1. The method of prevention of puerperal paresis in cows, including the introduction of a homeopathic drug, characterized in that a homeopathic drug "Larsen" administered before calving subcutaneously into biologically active points in the center of the front and rear lobes of the udder.
2. A method according to claim 1, characterized in that Larsen" administered in a dose of 0.5 ml.
3. A method according to claim 1, characterized in that the drug is administered bilaterally.
4. A method according to claim 1, characterized in that the drug is administered for 7 to 10 and 14 to 20 days before calving.
SUBSTANCE: analgesic preparations caused the onset of abuse headache are withdrawn; detoxification therapy, alternative anaesthesia, preventive and behavioural therapy follow. The detoxification therapy represents a 10-day therapeutic course according to the schedule: Cytoflavin 10 ml dissolved in 0.9% NaCl 200 ml is administered intravenously drop-by-drop daily in the morning and evening. Additionally, Milgamma 2.0 ml is injected intramuscularly daily in the morning; Reamberin 200-400 ml is administered intravenously drop-by-drop every second day.
EFFECT: treating the patients with abuse headache and reducing the number of recurrences.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine. What is described is a pharmaceutical composition containing licarbazepine acetate, preferentially eslicarbazepine acetate, in a combination with acceptable excipients, particularly a binding agent and a disintegrating agent. What is also described is a method for wet granulation for preparing the pharmaceutical composition.
EFFECT: composition is compacted as a tablet, which has reduced size and volume density.
79 cl, 10 ex
SUBSTANCE: composition has an action of the central nervous system; it is presented in the form of a solution, contains glycine, glycerol, a preserving agent and water. The invention also concerns a therapeutic agent and a biologically active addition based on the above composition.
EFFECT: group of inventions provides high bioavailability as the composition is presented in the liquid and ease of dosing.
12 cl, 2 tbl, 3 ex
SUBSTANCE: group of inventions relates to field of therapy and/or prevention of diseases in mammals, in particular humans. Group of inventions includes medication for treatment and/or prevention of cardiovascular disease, and/or inflammatory disease, and/or liver disease, and/or neurological disease, and/or steatosis by increasing content of polyunsaturated fatty acids in mammal's blood, representing dairy product of ruminants with reduced cholesterol content, where cholesterol content constitutes from 10 mg/100 g of fat to 150 mg/100 g of fat, as well as application of dairy product of ruminants with reduced cholesterol content, in which cholesterol content constitutes from 10 mg/100 g of fat to 150 mg/100 g of fat, for treatment and/or prevention of cardiovascular disease, and/or inflammatory disease, and/or liver disease, and/or neurological disease, and/or steatosis by increasing content of polyunsaturated fatty acids in mammal's blood.
EFFECT: obtaining medication for treatment and/or prevention of cardiovascular disease, and/or inflammatory disease, and/or liver disease, and/or neurological disease, and/or steatosis.
18 cl, 5 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to biotechnology. What is presented is the strain Bifidobacterium longum NCIMB 41676 possessing the immunomodulatory action. The above strain is applicable as an anti-infectious probiotic strain. What is also presented is a probiotic formulation containing the above strain and a carrier for oral administration. What is also presented is using the formulation as a cognitive function enhancer for preventing the central nervous system disorders, such as Alzheimer disease, schizophrenia and/or mild cognitive disorders. Alternatively, what is used is the formulation for preventing an inflammation related to obesity, for preventing metabolic disorders related to obesity.
EFFECT: group of inventions provides increasing anti-inflammatory cytokine IL-10 and decreasing proinflammatory cytokines and lipopolysaccharide induced HfkB activity.
37 cl, 16 dwg, 6 tbl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new compounds of formula I, wherein R1 and R2 are identical or different and specified in an alkyl or alkenyl hydrocarbon chain; the R3 group values split by lipase are specified in the patient claim. R4 and R5 are independently hydrogen or C1-C7alkyl; R6 represents hydrogen or C1-C7alkyl; and R7 and R8 are independently hydrogen or C1-C7alkyl. The invention also refers to using compounds of formulas ,
which are introduced into the mammalian biological system and increase the cell concentrations of specific sn-2 substituted ethanolamine-plasmalogens.
EFFECT: compounds are applicable in treating or preventing the age-related disorders associated with high membrane cholesterol, high amyloids and low plasmalogens, such as neurodegeneration, cognitive disorder, dementia, cancer, osteoporosis, bipolar disorder and vascular diseases.
11 cl, 18 dwg, 7 ex
SUBSTANCE: application of a mixture of triterpenoids, containing β-amyrin 27.48 wt %, α-amyrin 27.52 wt %, moretenol 25.52 wt %, lupeol 19.48 wt % or butyro-lignans - arctiin or arctigenin, separated from Alfredia cemua (L.) Cass., as a medication, possessing a cerebroprotective action. The said mixture of triterpenoids or butyro-lignans - arctiin or arctigenin, separated from Alfredia cemua (L.) Cass., possess the expressed cerebroprotective action.
EFFECT: increased efficiency of the medication application.
1 tbl, 2 ex
SUBSTANCE: after establishing a diagnosis of delirium associating dementia and a diagnosis of hallucinosis related to a cerebral new growth in the acute postoperative period, the following therapeutic regimen is prescribed: Sonapax 60 mg/day + Melaxen 18 mg/day (9 mg at 2 p.m. and 9 mg for the night) for three days, then a dose of Sonapax is gradually decreased to 30 mg/day. The therapy is continued for a week after reducing the symptoms.
EFFECT: effective treatment of the mental disorders in the neurooncological patients by the effective combination of low doses of the neuroleptic and the preparation of melatonin.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula (I) and their pharmaceutically acceptable salts, wherein A is thiazolyl, oxazolyl, thienyl, furyl, imidazolyl, pyrazolyl or oxadiazolyl (structures of which are presented in cl.1 of the patent claim), R1 represents C1-6alkyl; R2 represents (i) phenyl substituted by halogen; C1-6alkyl optionally substituted by morpholine or C1-6dialkylamino; C1-6alkoxy optionally substituted by halogen; or heterocyclyl, wherein a heterocyclyl substitute is specified in morpholine; pyrazolyl optionally substituted by C1-6alkyl; piperidinyl; pyrrolidinyl; oxadiazolyl substituted by C1-6alkyl; furyl substituted by C1-6alkyl; dioxydoisothiazolidinyl; triazolyl; tetrazolyl substituted by C1-6alkyl, tridiazolyl substituted by C1-6alkyl; thiazolyl substituted by C1-6alkyl; pyridyl; or pyrazinyl; (ii) substituted or unsubstituted heterocyclyl specified in quinolinyl; pyridyl substituted by C1-6alkoxy or morpholinyl; or benzo [d] [1, 2, 3] triazolyl substituted by C1-6alkyl; R3 represents phenyl substituted by 2 or 3 substitutes specified in halogen; C1-6alkyl; C1-6alkoxy optionally substituted by halogen; hydroxy group; cyano; or -C(=O)ORa, wherein Ra represents phenyl; R4 represents hydrogen, C1-6alkyl or C1-6halogenalkyl. The invention also refers to a pharmaceutical composition containing the compounds of formula (I), a method for PDE10 inhibition, a method of treating neurological disorders, and to intermediate compounds: 2-(4-chlor-3,5-dimethoxyphenyl)furan and 4-(5-methyl-1,3,4-thiadiazol-2-yl)benzaldehyde.
EFFECT: compounds of formula (I) as PDE10 inhibitors.
39 cl, 13 ex, 2 tbl, 77 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new chromone derivatives of general formula
wherein: R1 represents one or more identical or different substitutes on a benzene ring, each of which independently represents a hydrogen atom, or a halogen atom, or C1-4 alkoxy group, or OH group. or group -O(CH2)nO-, wherein n=1 or 2, R2 represents a hydrogen atom, or C1-4 alkyl group; A and B independently represent either a nitrogen atom, or a carbon atom; R3 represents a hydrogen atom or one or more identical or different substitutes specified in a group consisting of: a halogen atom, C1-4 alkyl group, C1-4 alkoxy group, group -O(CH2)nO-, wherein n=1 or 2, group NO2, group NHSO2R4, group NHR5, OH group, C1-4 halogenoalkyl group, CN group, or R3 makes a ring condensed with a benzene ring bearing it, specified in a group consisting of indole, benzimidazole, carbostyril, benzoxazolone and benzoxazolone and benzimidazolone, R4 represents C1-4 alkyl group, or C1-4 dialkylamino group, or C1-4 alkoxyalkyl group, or C1-4 dialkylaminoalkyl group, R5 represents a hydrogen atom, or C1-4 alkylcarbonyl group, or C1-4 alkoxycarbonyl group, and to its pharmaceutically acceptable salts, as well as to methods for preparing them, and to based pharmaceutical compositions, and to using them as a therapeutic agent for central nervous system disorders, as long as they possess the D3 dopaminergic ligand properties.
EFFECT: preparing the compositions for treating central nervous system disorders, as long as they possess the D3 dopaminergic ligand properties.
17 cl, 1 dwg, 2 tbl, 33 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of obtaining microcapsules of medication, which possess supermolecular properties, by method of precipitation with non-solvent, characterized by the fact that as medication applied is powder of unabi berries, preliminarily dissolved in butanol, as envelope - carrageenan, which is precipitated from solution in acetone by addition as non-solvent of ethanol and water, with the following drying at room temperature.
EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules (increase of output by weight).
2 ex, 18 dwg
SUBSTANCE: method includes the preparation of a carious cavity, opening the tooth cavity, creation of an access to root canals, extension of their orifice. Removal of a decayed material from the root canals and their drug treatment are carried out. After that, performed are: wide opening of the apical tooth orifice, mechanical and drug removal of periapical pathological exudative formations in the focus of periapical inflammation through the root canal. Before filling the canal with a filling material the gel "Lamifaren" is introduced into the focus of periapical destruction. Such introduction is performed three times after a day under temporary stopping. The gel "Lamifaren" is introduced inside in a dose of 50 g 2 times per day for 30 days.
EFFECT: application of the invention accelerates bone tissue regeneration due to the active release of an active substance calcium alginate, provides stable remission due to local and systemic detoxifying effect.
SUBSTANCE: invention relates to medicine, namely to methods of purification and health improvement of an organism. For this purpose therapeutic starvation for not fewer than 5 days in case of a 7-day programme and for not fewer than 7 days in case of a 9-day programme is carried out. The duration of a recovery period constitutes two days. Food intake is realised nine times per day each day both in the process of therapeutic starvation and in the recovery period. In the period of therapeutic starvation the first food intake includes bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "APITOK" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The second food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The third food intake supposes an intake of bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The fourth food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The fifth food intake consists of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The sixth food intake consists of bee products "APIGRANULES 2" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and one glass of still mineral water. The seventh food intake includes tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The eighth food intake supposes an intake of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The ninth intake of food includes depressant tea, including mint grass, valerian root, fennel seeds, cumin seeds, epilobium or strawberry leaves and one glass of apple-carrot juice. In the recovery period in 1-st, 2-nd, 3-rd, 4-th and 6-th intakes of food the composition of products remains the same as in the process of starvation. For the fifth intake of food the patients take tea black or green with ginger, one teaspoon of honey and vegetable soup. For the seventh intake of food the patients take tea black or green with ginger, "MILK COCKTAIL WITH CHITOSAN". The eighth intake of food includes tea black or green with ginger, one teaspoon of honey, "APICAMPA" cereal. The ninth intake of food for the recovery period includes a baked apple, depressant tea. In addition, a number of procedures are carried out after each food intake during the period of therapeutic starvation and the recovery period. After the first food intake gymnastics "5 Tibetan pearls" is realised. After the second food intake exercises on training apparatuses, procedures of press-therapy, electrolypolysis and myostimulation are realised. After the third food intake exercises of therapeutic physical training or aerobics are performed. After the fourth food intake a rest in form of a walk, a halotherapy session, combined with a session of relaxation therapy are realised. After the fifth food intake a course of strip-plastic is carried out. After the sixth food intake massage by manual application with a peloid-based mixture or manual massage with honey is carried out. After the seventh food intake an infra-red sauna, shower, phytobath with medicinal herbs, honey, ginger, lemon juice is taken. After the eighth food intake a shower is taken.
EFFECT: method ensures effective health improvement of the organism with the preservation of the full value life style and a sense of a comfortable state in the starvation period, reduction of recovery period term after starvation, purification of the organism without loading on the gastrointestinal tract, weight loss, and improvement of the general state and workability of the patients.
3 tbl, 7 ex
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for the treatment of local skin I-II degree radioreactions on irradiation fields after neutron therapy in patients with head and neck malignancies. For this purpose the applications of ozonised sunflower oil with peroxide number 18% and acid number 71 mg KON/g are performed on the area of the affected skin. The impact is performed after a session of neutron therapy 1-2 times per day for 4-5 days.
EFFECT: method ensures the reduction of the number of radioreactions and skin injuries due to optimally selected parameters of the applied medication, capable of the fast arrest of pain syndrome, reduction of oedema of surrounding tissues, wound-healing action in specific irradiation conditions.
4 dwg, 1 ex
SUBSTANCE: invention relates to versions of cationic polyelectrolytic composition for application in personal care products and household chemicals and method of its obtaining. Composition includes: 1) cationic synthetic water-soluble polyelectrolyte, which contains (meth)acrylamide polymer and one or several of the following substances: I) cationic (meth)acrylamide monomer, and II) cationic monomer of (meth)acrylic acid, and III) hydrolysis-resistant cationic monomers, where polyelectrolyte has weight average molecular weight from approximately 10000 to approximately 2000000, charge density from, 0.001 to 2.5 meq./g, and level of acrylamide monomer that did not react constitutes less than 50 ppm, 2) surface-active substance and 3) solvent.
EFFECT: preparations, obtained on the base of composition, possess higher transparency.
17 cl, 3 dwg, 12 tbl, 106 ex
SUBSTANCE: invention relates to a method of producing shea oil microcapsules. Said method is characterised by that shea oil is dissolved in dimethyl sulphoxide, the obtained mixture is dispersed in a suspension of sodium alginate in butanol in the presence of E472c, followed by addition of isopropanol and water, filtering and drying the obtained suspension of microcapsules, wherein the nucleus/polymer ratio in the microcapsules is 1:1 or 1:3.
EFFECT: invention provides a simple and fast process of producing shea oil microcapsules and increases mass output.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to using medicinal plant Gelsemium elegans Benth. and Datura metel L. blossom in preparing a therapeutic agent for eliminating or relieving acute and persistent withdrawal symptoms caused by taking a dependence-producing substance. The invention refers to pharmaceutical compositions (versions) for eliminating or relieving acute or persistent withdrawal symptoms caused by taking the dependence-producing substance, and containing Gelsemium elegans Benth. and Datura metel L. blossom in certain relations.
EFFECT: pharmaceutical compositions containing Gelsemium elegans Benth and Datura metel L. blossom are effective for the individuals suffering drug dependence.
15 cl, 12 ex
SUBSTANCE: invention relates to method of simultaneous obtaining of two flavonoids - patuletine and its 7-O-β-D-glucopyranoside - patuletrine. Method consists in the following: milled edge petals of flower of high flavonoid sorts of tagetes patula are extracted with hexane, dried and r-extracted with chloroform, chloroform extract is concentrated, dry residue is dissolved in mixture of petroleum ether - chloroform, precipitated sediment is filtered, washed with petroleum ether and dried, obtained dry powder is dissolved in mixture chloroform - ethanol, precipitated sediment is filtered, washed with petroleum ether and dried with obtaining patuletine. Then, extraction of raw material, which remains after chloroform processing, is carried out with ethanol, alcohol extract is filtered and concentrated, after that, water residue is subjected to liquid phase extraction with ethylacetate, then, organic layer is concentrated, dry residue is dissolved in mixture chloroform - ethylacetate, precipitated sediment is filtered, washed with cooled ethylacetate, solution of hydrochloric acid in ethanol, ethanol and ethylacetate and dried, dry powder is dissolved in mixture ethylacetate-ethanol, precipitated sediment is filtered, washed with ethylacetate and dried with obtaining patuletrine.
EFFECT: method makes it possible to obtain highly pure samples of patuletine and patuletrine, as well as increase target product output.
4 dwg, 3 tbl, 4 ex
FIELD: food industry.
SUBSTANCE: imitator of odour of hallucinogenic plant i.e. Hawaiian baby woodrose for sniffer dogs training contains an inert carrier and an odour substance; the imitator is specifically as follows: the odour substance is represented by a mixture containing benzoic acid and "rose" food flavouring agent.
EFFECT: sniffer dogs preparation for the said hallucinogenic substance search.
6 cl, 7 ex
SUBSTANCE: medication includes 7.0-9.0 wt % of a dried thick fraction of a product of hazel dry sublimation, 0.025-0.033 wt % of hydrochloride anaprilin, 36.0-38.0 wt % of sodium hydrocarbonate, 24.5-25.5 wt % of boric acid, 12.0-16.0 wt % of phthalic acid, 5.5-7.5 wt % of sodium carboxymethylcellulose, 0.8-1.0 wt % of sodium dodecylsulphate, 0.45-0.55 wt % of calcium stearate and 5.5-10.8 wt % of glucose.
EFFECT: invention increases the therapeutic and preventive efficiency of treatment of postnatal endometritis in cows and cow-heifers.
FIELD: medicine, oncology, amino acids.
SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.
EFFECT: valuable medicinal antitumor properties of preparation.
8 cl, 4 tbl, 2 dwg, 4 ex